patrick.net

Cancer patients are cured by themselves by taking fenbenzole

Cancer patients are cured by themselves by taking fenbenzole

癌症患者服用芬本唑自己治愈康了
https://open.substack.com/pub/fenbendazole/p/metastatic-squamous-cell-cancer-age

Fenbendazole Can Cure Cancer presents Case Reports of people who have treated their own cancers along with other articles to help understand how fenbendazole works to treat cancer. Previous articles covering other cancers are in the Archives link.

Metastatic Squamous Cell Cancer, age 77, Female

SM is a 77 year old, 5’4”, 130 lb woman, and is living proof that a dire prognosis is not an insurmountable barrier. Her journey is one of resilience, research, and ultimately, a reclaiming of health against formidable odds.

On March 2021, SM was diagnosed with metastatic squamous cell carcinoma. Swollen lymph nodes on her left clavicle, confirmed malignant by a general surgeon’s biopsy and further delineated by a PET scan. SM’s oncologist delivered the verdict: four months to live. Curative treatment was off the table; only palliative care was offered.

Initially, SM submitted to conventional palliative treatments. She underwent a course of chemotherapy, specifically cisplatin combined with taxol. The side effects, compounded by the intense pain from the significantly enlarged lymph nodes, were debilitating. Consequently, nine rounds of radiation were administered in an attempt to alleviate these acute symptoms.

The pivotal moment came through a connection at church, where a fellow member introduced SM to fenbendazole. Armed with this information, she made a decisive move to start a daily regimen of 222 mg of fenbendazole, simply swallowing the granules with water. SM informed her oncologist of her self-directed treatment; while he did not endorse it, her conviction was unwavering.

The impact of the fenbendazole on her cancer was undeniable and swift. Within a few months of starting fenbendazole, a palpable shrinkage of the lymph nodes occurred. By the six-month mark, the persistent pain that had plagued SM was entirely gone. The true turning point arrived in March 2022 when imaging confirmed she was completely cancer-free. This cancer-free status has been meticulously monitored and consistently reaffirmed by CT scans every four months since that date.

Subscribe to receive new posts. It’s free.

Subscribed
More recently, from the end of 2023 until December 2024, she incorporated Keytruda into her regimen “just to be sure” under the advice of her doctor, but SM has since discontinued it due to adverse side effects of that drug. SM’s vigilance with fenbendazole continues, now adhering to a cycle of 222 mg daily for four days, followed by a three-day pause.

Importantly, throughout SM’s fenbendazole treatment, she experienced no noticeable adverse side effects.

SM’s decision to take fenbendazole was met with skepticism by her medical team, who largely discounted its potential. When she shares her fenbendazole experience with others, their reaction is often one of shock, primarily due to her willingness to employ a therapy considered unregulated, or outside the box, for cancer.

Timeline of Events, Diagnoses, Treatments and Outcomes

March 2021: Diagnosed with metastatic squamous cell carcinoma via biopsy of left clavicular lymph nodes and PET scan. Given a 4-month prognosis, offered palliative care only.
Mid-2021 (approx.): Underwent chemotherapy (Cisplatin and Taxol) followed by 9 rounds of radiation for pain and large lymph nodes.
Late 2021 (approx.): Initiated self-treatment with Panacur (fenbendazole) 222 mg daily, taken with water. Oncologist informed and skeptical.
Early 2022 (within months of starting fenbendazole): Observed shrinkage of lymph nodes.
Mid-2022 (approx. 6 months after starting fenbendazole): Pain completely resolved.
March 2022: Declared cancer-free, confirmed by imaging (CT scans).
March 2022 - Present: Remained cancer-free, verified by CT scans every 4 months.
End of 2023 - December 2024: Underwent Keytruda treatment.
May 19, 2025: Continues fenbendazole 222 mg on a 4-days-on, 3-days-off cycle.
Summary

This Case Report details the experience of a 77-year-old female diagnosed in March 2021 with metastatic squamous cell carcinoma and given a four-month prognosis. After palliative conventional chemotherapy and radiation yielded significant side effects, she independently initiated treatment with fenbendazole (222 mg daily). She reported lymph node shrinkage within months, pain resolution by six months, and achieved cancer-free status by March 2022 (one year), consistently confirmed by imaging. SM continues a maintenance dose of fenbendazole and reports no side effects, having defied her initial prognosis of 4 months by 4 years so far.

Thanks for reading Fenbendazole Can Cure Cancer! To receive new Case Reports you must subscribe! Subscribe for free.
芬本唑可以治愈癌症呈现案例报告，这些人与其他文章一起治疗了自己的癌症，以帮助了解芬本唑如何致力于治疗癌症。 以前涵盖其他癌症的文章在档案链接中。

转移性鳞状细胞癌，77岁，女性

SM是一名77岁的5'4英寸，130磅的女性，并证明了可怕的预后并不是无法克服的障碍。她的旅程是韧性，研究，最终是针对强大赔率的健康恢复。

2021年3月，SM被诊断出患有转移性鳞状细胞癌。 左锁骨上的淋巴结肿胀，被普通外科医生的活检证实，并通过PET扫描进一步描述了淋巴结。 SM的肿瘤科医生作出了判决：四个月的生存。 治疗疗法脱离了桌子； 仅提供姑息治疗。

最初，SM提交给常规姑息治疗。 她接受了化学疗法，特别是顺铂与紫杉醇相结合。 副作用因淋巴结显着肿大的剧烈疼痛而使副作用令人衰弱。 因此，为减轻这些急性症状而进行了九轮辐射。

关键时刻是通过教堂的联系，一位成员将SM介绍给芬本唑。 凭借这些信息，她做出了决定性的举动，开始每天的芬本唑222毫克，只是用水吞下颗粒。 SM告诉她肿瘤科医生的自我指导治疗； 尽管他不认可它，但她的信念坚定不移。

芬本唑对她的癌症的影响是不可否认和迅速的。 在开始芬本唑的几个月内，发生了明显的淋巴结收缩。 到了六个月的标记，困扰SM的持续疼痛已经消失了。 真正的转折点于2022年3月到达，当时成像确认她完全没有癌症。 自该日期以来，每四个月，每四个月CT扫描就对这种无癌症状态进行了仔细的监测，并始终如一地重申。

订阅以接收新帖子。 免费。

订阅
最近，从2023年底到2024年12月，在医生的建议下，她将Keytruda纳入了“只是为了确保”的方案，但此后SM由于该药物的不良副作用而中止了。 SM对芬本唑的警惕仍在继续，现在每天遵守222毫克的周期，持续了四天，随后停了三天。

重要的是，在SM的芬本唑治疗中，她没有明显的不良副作用。

她的医疗团队对SM征服Fenbendazole的决定遭到了怀疑，后者在很大程度上违背了其潜力。 当她与他人分享自己的芬本唑经验时，他们的反应通常是震惊的一种，这主要是由于她愿意采用一种被认为是不受管制的疗法或外部的癌症治疗。

事件，诊断，治疗和结果的时间表

2021年3月：通过左锁骨淋巴结和PET扫描的活检被诊断为转移性鳞状细胞癌。 考虑到4个月的预后，仅提供姑息治疗。
2021年中期（大约）：接受化学疗法（顺铂和紫杉醇），然后进行9轮辐射，用于疼痛和大淋巴结。
2021年末（大约）：用水222毫克的Panacur（Fenbendazole）开始自我治疗，用水服用。 肿瘤学家告知和持怀疑态度。
2022年初（在开始芬本唑的几个月内）：观察到的淋巴结收缩。
2022年中期（大约开始芬本唑之后6个月）：疼痛完全解决。
2022年3月：通过成像（CT扫描）确认为无癌症。
2022年3月 - 目前：保持无癌症，每4个月通过CT扫描验证。
2023年底 - 2024年12月：接受了KeyTruda治疗。
2025年5月19日：在4天，3天的周期中继续芬本唑222毫克。
概括

该病例报告详细介绍了一名77岁女性，该女性于2021年3月诊断出患有转移性鳞状细胞癌的经验，并进行了四个月的预后。 姑息性常规化疗和放射线产生显着的副作用后，她独立地用芬班丹唑（每天222 mg）开始治疗。 她报告说，淋巴结在几个月内收缩，疼痛减少了六个月，并在2022年3月（一年）之前达到了无癌状态，并始终通过影像学证实。 SM继续维持芬本唑的维护剂量，并没有报告副作用，但迄今为止她的最初预后却没有4个月的最初预后。

感谢您阅读芬本唑可以治愈癌症！ 要接收新案例报告，您必须订阅！ 免费订阅。